Top 50 Gene Editing

Prime Medicine utilizes Prime Editing, a precise gene editing technology that enables the targeted replacement of faulty DNA sequences without causing double-strand breaks. This approach aims to directly correct genetic mutations responsible for debilitating diseases, potentially offering long-lasting therapeutic benefits.

The startup has developed a gene-editing technology that enables scalable digital genome engineering through a user-friendly interface. This technology produces low-cost libraries of thousands of designer protein and genome variants, each with specific and trackable mutations, facilitating efficient research and development in genetic engineering.

EdiGene develops genome editing technologies, including the LEAPER platform for in vivo RNA base editing and the MAGIC platform for allogeneic cell therapies, to address genetic diseases and cancer. Their high-throughput genome editing screening capabilities enable precise therapeutic interventions, enhancing treatment efficacy and patient outcomes.

Pencil Biosciences is developing a fully synthetic, modular gene editing technology that operates independently of CRISPR, enabling precise modulation of genetic sequences. This technology aims to provide new therapeutic options for patients with rare diseases by addressing the limitations of existing gene editing methods.

Volta Labs develops scalable automation solutions for genetic engineering using advanced CRISPR and synthetic biology techniques. This technology enhances the efficiency and precision of gene editing, addressing the challenges of time-consuming and error-prone manual processes in genetic research and development.

Amber Bio is developing a novel RNA writing platform that enables multi-kilobase gene edits to target diverse mutations in patient populations with previously undruggable conditions. This approach eliminates the need for separate therapies for each mutation, providing a scalable solution for genetic medicine.

Beam Therapeutics develops precision genetic medicines using base editing technology to enable targeted modifications of DNA sequences. This approach addresses the limitations of traditional gene editing methods, offering potential treatments for genetic disorders with improved accuracy and reduced off-target effects.

The startup develops a healthcare technology platform that reprograms recombinases for precise gene editing, enabling the restoration of health in patients with severe conditions. Its technology provides clients with disease-modifying product candidates, enhancing the therapeutic potential of gene editing.

Mammoth Biosciences develops CRISPR-Cas-based gene editing therapeutics and diagnostics to enable precise in vivo applications for serious diseases and molecular detection. Their technology addresses the challenges of gene delivery and expands testing capabilities, providing permanent solutions for unmet medical needs.

Develops proprietary genomic editors that target the root causes of genetic diseases by selecting optimal editing tools based on disease-specific pathology. This approach enables the discovery and development of potentially curative genomic medicines, with a focus on liver and central nervous system disorders.

GenEdit utilizes the NanoGalaxy® delivery platform to enhance the safe and efficient delivery of CRISPR-Cas9 gene editing therapies for genetic diseases. This technology addresses the challenge of limited access to effective genetic medicines, enabling broader patient treatment options.

Faze Medicines is a biotechnology company focused on developing targeted therapies using advanced gene editing techniques to address genetic disorders. Their approach aims to enhance treatment precision and improve patient outcomes by directly modifying disease-causing genes.

Metagenomi utilizes metagenomics and machine learning to discover and develop novel genome editing systems that enable precise modifications to the human genome. This technology addresses the limitations of existing gene editing methods by providing a versatile toolbox capable of targeting specific sites for therapeutic interventions.

Ascidian Therapeutics develops a proprietary RNA exon editing platform that enables precise post-transcriptional modifications to replace multiple contiguous exons, addressing genetic mutations that vary among patients. This technology allows for the production of full-length, functional proteins at appropriate levels and in the correct cells, providing a safer alternative to traditional gene editing methods.

Brink Therapeutics develops next-generation recombinase enzymes designed for ultra-precise and efficient gene editing. These enzymes aim to enable large-scale production of cell and gene therapies for treating cancer and genetic disorders.

Kano Therapeutics develops circular single-stranded DNA (ssDNA) templates using a fermentation-based production method to enable precise gene-length DNA insertion with higher efficiency and lower off-target effects. This technology addresses the limitations of existing gene editing tools by providing a safe and effective means for genomic engineering, facilitating the transition from gene editing to complete genetic cures.

Hudson River Biotechnology utilizes CRISPR-based gene editing to enhance specific traits in plants, improving crop quality and yield while minimizing agricultural inputs. Their targeted delivery systems for agrochemicals further reduce environmental impact, addressing the inefficiencies in traditional farming practices.

Scribe Therapeutics engineers CRISPR-based therapeutics to modify genetic predispositions, specifically targeting cardiometabolic diseases. By creating safe and effective gene-editing solutions, the company aims to empower individuals to take control of their health outcomes rather than being limited by inherited conditions.

Twelve Bio develops CRISPR-Cas12a diagnostic technology that enables precise detection and modification of DNA sequences. This technology addresses the need for accurate genetic diagnostics and targeted gene editing to treat genetic disorders and diseases.

Modalis is a biotech company that utilizes CRISPR technology to develop targeted therapeutics for genetic disorders, specifically focusing on conditions like congenital muscular dystrophy. Their approach aims to provide precise gene editing solutions to address the underlying genetic causes of these diseases.

Colossal utilizes advanced gene editing techniques to reconstruct the DNA of extinct species, such as the woolly mammoth, to facilitate their de-extinction and reintroduction into ecosystems. This approach aims to combat biodiversity loss and restore ecological balance by reviving keystone species that have significantly impacted their environments.

The startup develops genetic medicines utilizing genome editing and engineering techniques to create pharmaceutical and biological preparations for human therapeutics. This approach enables researchers to effectively target and modify genetic disorders, improving treatment outcomes for patients.

The company develops genome editing-based therapies for genetic disorders, oncology, and organ transplants. Their technology enables precise genetic recombination to create off-the-shelf treatments for previously incurable diseases.

Tessera Therapeutics is pioneering Gene Writing™, a genome engineering technology that enables precise alterations to the human genome to treat genetic diseases at their source. This platform addresses the need for permanent and potentially curative therapies by delivering therapeutic genetic modifications directly to targeted tissues without the use of viral vectors.

AIRNA is developing RNA editing therapies to treat rare and common diseases by precisely modifying RNA sequences to correct genetic mutations. This approach aims to enhance patient health outcomes by targeting the underlying causes of genetic disorders.

The startup develops optimized CRISPR guide RNA and edited cells for the cell biology and gene therapy research markets, offering products such as CRISPR reagents and gene knockout kits. Their solutions enable researchers to perform genome engineering more efficiently and reliably, facilitating advancements in genetic research and therapeutic applications.

Alia Therapeutics is developing next-generation gene-editing therapies that utilize precise genome editing techniques to target and correct mutations responsible for rare genetic diseases. By focusing on the efficacy and durability of these treatments, the company aims to provide long-lasting cures that address the root causes of genetic disorders.

Pixel Biosciences specializes in the synthesis of customized RNA and DNA reagents, including sgRNA and CRISPR gene editing tools, utilizing their proprietary nMECA technology to significantly reduce impurities in mRNA synthesis. Their solutions enhance the precision and efficiency of gene editing and drug development processes in research and clinical applications.

The startup develops gene editing therapeutics that target and disrupt viral genes associated with neurotrophic viruses, transforming them into safe and effective treatments. This enables healthcare providers to effectively manage diseases caused by viral infections, improving patient outcomes.

Resurrect Bio utilizes gene editing techniques to resurrect immune resistance genes in crops, enhancing their ability to combat evolving plant diseases. This approach addresses the increasing threat of crop diseases exacerbated by climate change and modern monoculture practices, which have diminished genetic diversity and immune resilience in agricultural species.

Editpep develops a class of peptides designed to deliver CRISPR enzymes effectively, enhancing the precision of gene editing applications. This technology addresses the challenge of efficient and targeted delivery in CRISPR therapies, improving the potential for therapeutic outcomes.

ClimateCrop utilizes targeted gene editing to enhance starch storage in plant leaves, improving photosynthetic efficiency and enabling plants to yield more biomass and fruit with the same resource inputs. This technology addresses the increasing global demand for crops by enhancing plant resilience to drought and heat while maintaining nutrient quality.

MyFloraDNA operates a DNA plant laboratory that utilizes CRISPR technology for precise gene editing to develop allergy-free peanuts, targeting specific allergenic compounds without altering the peanuts' natural qualities. This approach aims to significantly reduce allergy-related health incidents for millions of peanut allergy sufferers.

GenEditBio develops precision gene editing technologies to create targeted in vivo gene therapies for genetic diseases. Their platform utilizes advanced gene editing tools to address a wide range of genetic mutations, offering safe and effective treatment options.

Biographica utilizes biology-aware machine learning and high-throughput sequencing to identify and prioritize genetic targets for crop gene-editing, addressing the challenge of inefficient gene selection that often results in high costs and low success rates. By combining in silico modeling with in vivo validation, the platform enhances the precision of genomic modifications, enabling the development of more productive and climate-resilient crops.

Intellia Therapeutics develops in vivo CRISPR‑Cas9 gene‑editing medicines that directly correct disease‑causing mutations in patients with severe monogenic disorders. Its platform integrates guide‑RNA design, lipid nanoparticle/AAV delivery, safety screening, and GMP manufacturing to advance candidates from target discovery through clinical trials, aiming for single‑dose curative treatments.

Acrigen Biosciences develops precision gene editing systems utilizing proprietary αCas and μCas CRISPR-Cas nucleases paired with engineered anti-CRISPR proteins to enhance the accuracy and safety of genetic therapies. The company aims to address genetic disorders by providing targeted and efficient gene editing solutions for human therapeutics.

InSyte Bio develops precision gene editing technologies to enhance the efficiency of biopharmaceutical production processes. The company addresses the challenges of high costs and lengthy timelines in drug development by streamlining genetic modifications for improved yield and consistency.

InEdita Bio has developed a proprietary genome editing platform utilizing CRISPR technology to create crops with enhanced resistance to pests and diseases, while improving nutrient acquisition efficiency. This technology reduces the reliance on chemical fertilizers and pesticides, addressing the challenges of food security and environmental sustainability in agriculture.

GeneNeer utilizes its proprietary Superlines technology for precise gene editing and trait expression control in crops, enhancing their resilience to climate change. This approach accelerates the development of improved seed varieties, addressing the urgent need for sustainable agricultural solutions to ensure global food security.

The startup develops genome editing technology that enables the cultivation of bacteria to modify and control microbiomes for therapeutic applications. This approach allows researchers to conduct precise gene editing and microbiome engineering, facilitating the development of targeted treatments for various health conditions.

Yaotang Bio develops gene editing therapies by combining LNP (Lipid Nanoparticle) delivery systems with advanced gene editing technology. This approach aims to precisely deliver genetic material to target cells for therapeutic applications.

C4U Corporation specializes in the research and development of gene editing technologies, focusing on CRISPR-based methods to precisely modify genetic sequences. The company aims to address genetic disorders and enhance agricultural traits, providing targeted solutions for health and food security challenges.

HuidaGene Biotechnology Co., Ltd develops CRISPR-based gene-editing tools and therapies targeting genetic disorders in ophthalmology, neurology, and neuromuscular diseases. Their technology aims to repair genetic mutations responsible for life-threatening conditions, such as Duchenne Muscular Dystrophy and inherited retinal dystrophies.

Reforgene Medicine utilizes gene editing and genomic technology to develop curative therapies for genetic diseases, specifically targeting conditions like thalassemia and Usher syndrome. Their approach aims to provide lifelong cures through a single administration of gene editing treatments, addressing the significant unmet medical needs of patients suffering from these hereditary disorders.

The startup develops targeted therapeutics that utilize gene editing techniques to treat cancer, focusing on genetic alterations that conventional therapies cannot reach. This approach enables patients to receive personalized treatment options that improve their health outcomes and quality of life.

The startup provides customized genetic modeling services using CRISPR-facilitated gene targeting in embryonic stem cells to create specific mutations for research. This technology enables clients to efficiently develop knockout mice and complex genetic modifications for studying gene function and disease mechanisms.

Stat Labs develops novel CRISPR-based gene editing tools for therapeutic applications. Their technology aims to precisely modify DNA sequences to correct genetic mutations and treat a range of diseases.

Neoclease engineers highly precise and efficient gene-editing nucleases using a generative AI platform. Their technology enables targeted therapeutic interventions for genetic disorders and complex diseases, including novel approaches for difficult-to-access tissues.

Primera Therapeutics develops gene editing therapies to correct mutations in mitochondrial DNA, the root cause of many inherited diseases. Their therapies aim to provide a curative approach for severe childhood diseases, chronic kidney disease, and metabolic disorders linked to mitochondrial dysfunction.